

Boston Scientific

## **Boston Scientific to Implement All Recommendations of Heart Rhythm Society Report**

PRNewswire-FirstCall  
NATICK, Mass.  
(NYSE:BSX)

NATICK, Mass., April 26 [/PRNewswire-FirstCall/](#) -- Boston Scientific Corporation (NYSE: BSX) today announced that it plans to implement all the recommendations contained in a draft report by the Heart Rhythm Society (HRS). The report was issued today and includes recommendations for the surveillance, analysis and performance reporting of pacemakers and implantable cardioverter defibrillators (ICDs). Jim Tobin, President and Chief Executive Officer of Boston Scientific issued the following statement, commenting on the report:

"This is a sound and constructive report whose recommendations can and must be implemented. Boston Scientific plans to implement all the recommendations that apply to manufacturers. In particular, we believe an industry-wide, independent committee of outside experts should be established. Guidant deserves great credit for demonstrating early leadership and already implementing a number of the measures recommended by the HRS. Implementing the HRS recommendations will help ensure timely and transparent clinician communication and patient safety. We clearly understand and acknowledge our need to do better in this area. We commend the HRS for its report, and we look forward to continuing to work with them on issues of importance to physicians and patients."

Boston Scientific completed its acquisition of Guidant Corporation on April 21.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: <http://www.bostonscientific.com/>.

This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.

CONTACT: Milan Kofol  
508-650-8569  
Investor Relations  
Boston Scientific Corporation

Paul Donovan  
508-650-8541  
Media Relations  
Boston Scientific Corporation

SOURCE: Boston Scientific Corporation

CONTACT: Milan Kofol, Investor Relations, +1-508-650-8569, or Paul Donovan, Media Relations, +1-508-650-8541 both of Boston Scientific Corporation

Web site: <http://www.bostonscientific.com/>

---

<https://stage.mediaroom.com/bostonscientific/recommendations-heart-rhythm-society-report>